{"id":68346,"date":"2026-06-16T22:59:02","date_gmt":"2026-06-16T14:59:02","guid":{"rendered":"https:\/\/flcube.com\/?p=68346"},"modified":"2026-06-16T22:59:03","modified_gmt":"2026-06-16T14:59:03","slug":"everest-medicines-licenses-dmx-200-from-dimerix-ccr2-inhibitor-for-fsgs-targets-asia-pacific-markets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68346","title":{"rendered":"Everest Medicines Licenses DMX-200 from Dimerix \u2013 CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Everest Medicines<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1952:HKG\">HKG: 1952<\/a>) announced it has struck a <strong>licensing agreement<\/strong> with <strong>U.S. firm Dimerix Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/DXB:ASX\">ASX: DXB<\/a>), securing <strong>development and commercialization rights<\/strong> to <strong>DMX-200<\/strong> in <strong>Greater China, South Korea, and several Southeast Asian countries<\/strong>. The CCR2 inhibitor is currently in pivotal Phase III development for focal segmental glomerulosclerosis (FSGS) and has received Orphan Drug Designation from both the U.S. FDA and European Medicines Agency (EMA).<\/p>\n\n\n\n<h2 id=\"h-deal-overview\" class=\"wp-block-heading\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensing Company<\/strong><\/td><td>Everest Medicines (HKG: 1952)<\/td><\/tr><tr><td><strong>Partner<\/strong><\/td><td>Dimerix Limited (ASX: DXB)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>DMX-200 \u2013 small molecule CCR2 inhibitor<\/td><\/tr><tr><td><strong>Territories<\/strong><\/td><td>Greater China, South Korea, Southeast Asia<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Focal segmental glomerulosclerosis (FSGS)<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Phase III (ACTION3 pivotal study ongoing)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-financial-terms\" class=\"wp-block-heading\">Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Payment Type<\/th><th>Amount<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD 10 million<\/td><\/tr><tr><td><strong>Development\/Regulatory Milestones<\/strong><\/td><td>Up to USD 30 million<\/td><\/tr><tr><td><strong>Sales Milestones<\/strong><\/td><td>Up to USD 300 million<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered 10\u201315% on annual net sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The total potential deal value reaches <strong>USD 340 million<\/strong> plus royalties, reflecting the significant commercial potential of DMX-200 in the Asia-Pacific region&#8217;s underserved FSGS market.<\/p>\n\n\n\n<h2 id=\"h-drug-profile-amp-clinical-status\" class=\"wp-block-heading\">Drug Profile &amp; Clinical Status<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> DMX-200 \u2013 small molecule chemokine receptor 2 (CCR2) inhibitor<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Blocks CCR2 signaling pathway involved in inflammatory kidney disease progression<\/li>\n\n\n\n<li><strong>Current Study:<\/strong> ACTION3 Phase III pivotal trial for focal segmental glomerulosclerosis<\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong> Orphan Drug Designation from FDA and EMA<\/li>\n\n\n\n<li><strong>Therapeutic Innovation:<\/strong> Addresses significant unmet need in rare kidney disease with limited treatment options<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-significance\" class=\"wp-block-heading\">Market Impact &amp; Strategic Significance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Context<\/th><\/tr><\/thead><tbody><tr><td><strong>FSGS Prevalence<\/strong><\/td><td>Rare orphan disease affecting ~7\u201310 per 100,000 population globally<\/td><\/tr><tr><td><strong>Current Treatment Options<\/strong><\/td><td>Limited to immunosuppressants with significant side effects; no approved targeted therapies<\/td><\/tr><tr><td><strong>Asia-Pacific Opportunity<\/strong><\/td><td>Large patient population with high unmet need and growing healthcare access<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>First-in-class CCR2 inhibitor potential in key Asian markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">FSGS represents a significant unmet medical need with progressive kidney damage leading to end-stage renal disease in many patients. Current standard of care relies on non-specific immunosuppressive therapies with suboptimal efficacy and safety profiles.<\/p>\n\n\n\n<h2 id=\"h-strategic-rationale-for-everest-medicines\" class=\"wp-block-heading\">Strategic Rationale for Everest Medicines<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Expansion:<\/strong> Adds late-stage nephrology asset to complement existing pipeline<\/li>\n\n\n\n<li><strong>Geographic Leverage:<\/strong> Utilizes Everest&#8217;s established commercial infrastructure across Asia-Pacific<\/li>\n\n\n\n<li><strong>Orphan Drug Expertise:<\/strong> Builds on company&#8217;s experience with rare disease development and commercialization<\/li>\n\n\n\n<li><strong>Risk-Adjusted Value:<\/strong> Phase III asset with clear regulatory pathway and orphan drug protections<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">For Dimerix, the partnership provides crucial non-dilutive funding to support global development while ensuring optimal commercialization in key Asian markets through Everest&#8217;s local expertise and infrastructure.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The transaction exemplifies the growing trend of Western biotech companies partnering with Chinese pharmaceutical firms to access Asia-Pacific markets, while Chinese companies seek late-stage assets to diversify their pipelines beyond oncology into rare diseases and specialty therapeutic areas.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding partnership activities, clinical development timelines, regulatory approvals, and commercial expectations for DMX-200. Actual results may differ due to risks including Phase III trial outcomes, regulatory decisions, competitive dynamics, and execution of the collaborative development strategy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061600112_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026061600112_c.\"><\/object><a id=\"wp-block-file--media-1bd5b076-dba9-426a-9bc5-c2df53d733e6\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061600112_c.pdf\">2026061600112_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061600112_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-1bd5b076-dba9-426a-9bc5-c2df53d733e6\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Everest Medicines (HKG: 1952) announced it has struck a licensing agreement with U.S. firm Dimerix&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4805,4804,126,1164],"class_list":["post-68346","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-asx-dxb","tag-dimerix","tag-everest-medicines","tag-hkg-1952"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Everest Medicines Licenses DMX-200 from Dimerix \u2013 CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Everest Medicines (HKG: 1952) announced it has struck a licensing agreement with U.S. firm Dimerix Limited (ASX: DXB), securing development and commercialization rights to DMX-200 in Greater China, South Korea, and several Southeast Asian countries. The CCR2 inhibitor is currently in pivotal Phase III development for focal segmental glomerulosclerosis (FSGS) and has received Orphan Drug Designation from both the U.S. FDA and European Medicines Agency (EMA).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68346\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Medicines Licenses DMX-200 from Dimerix \u2013 CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets\" \/>\n<meta property=\"og:description\" content=\"Everest Medicines (HKG: 1952) announced it has struck a licensing agreement with U.S. firm Dimerix Limited (ASX: DXB), securing development and commercialization rights to DMX-200 in Greater China, South Korea, and several Southeast Asian countries. The CCR2 inhibitor is currently in pivotal Phase III development for focal segmental glomerulosclerosis (FSGS) and has received Orphan Drug Designation from both the U.S. FDA and European Medicines Agency (EMA).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68346\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-16T14:59:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-16T14:59:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68346#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68346\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest Medicines Licenses DMX-200 from Dimerix \u2013 CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets\",\"datePublished\":\"2026-06-16T14:59:02+00:00\",\"dateModified\":\"2026-06-16T14:59:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68346\"},\"wordCount\":485,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ASX: DXB\",\"Dimerix\",\"Everest Medicines\",\"HKG: 1952\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68346#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68346\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68346\",\"name\":\"Everest Medicines Licenses DMX-200 from Dimerix \u2013 CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-16T14:59:02+00:00\",\"dateModified\":\"2026-06-16T14:59:03+00:00\",\"description\":\"Everest Medicines (HKG: 1952) announced it has struck a licensing agreement with U.S. firm Dimerix Limited (ASX: DXB), securing development and commercialization rights to DMX-200 in Greater China, South Korea, and several Southeast Asian countries. The CCR2 inhibitor is currently in pivotal Phase III development for focal segmental glomerulosclerosis (FSGS) and has received Orphan Drug Designation from both the U.S. FDA and European Medicines Agency (EMA).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68346#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68346\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68346#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Medicines Licenses DMX-200 from Dimerix \u2013 CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest Medicines Licenses DMX-200 from Dimerix \u2013 CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets - Insight, China&#039;s Pharmaceutical Industry","description":"Everest Medicines (HKG: 1952) announced it has struck a licensing agreement with U.S. firm Dimerix Limited (ASX: DXB), securing development and commercialization rights to DMX-200 in Greater China, South Korea, and several Southeast Asian countries. The CCR2 inhibitor is currently in pivotal Phase III development for focal segmental glomerulosclerosis (FSGS) and has received Orphan Drug Designation from both the U.S. FDA and European Medicines Agency (EMA).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68346","og_locale":"en_US","og_type":"article","og_title":"Everest Medicines Licenses DMX-200 from Dimerix \u2013 CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets","og_description":"Everest Medicines (HKG: 1952) announced it has struck a licensing agreement with U.S. firm Dimerix Limited (ASX: DXB), securing development and commercialization rights to DMX-200 in Greater China, South Korea, and several Southeast Asian countries. The CCR2 inhibitor is currently in pivotal Phase III development for focal segmental glomerulosclerosis (FSGS) and has received Orphan Drug Designation from both the U.S. FDA and European Medicines Agency (EMA).","og_url":"https:\/\/flcube.com\/?p=68346","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-16T14:59:02+00:00","article_modified_time":"2026-06-16T14:59:03+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68346#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68346"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest Medicines Licenses DMX-200 from Dimerix \u2013 CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets","datePublished":"2026-06-16T14:59:02+00:00","dateModified":"2026-06-16T14:59:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68346"},"wordCount":485,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ASX: DXB","Dimerix","Everest Medicines","HKG: 1952"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68346#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68346","url":"https:\/\/flcube.com\/?p=68346","name":"Everest Medicines Licenses DMX-200 from Dimerix \u2013 CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-16T14:59:02+00:00","dateModified":"2026-06-16T14:59:03+00:00","description":"Everest Medicines (HKG: 1952) announced it has struck a licensing agreement with U.S. firm Dimerix Limited (ASX: DXB), securing development and commercialization rights to DMX-200 in Greater China, South Korea, and several Southeast Asian countries. The CCR2 inhibitor is currently in pivotal Phase III development for focal segmental glomerulosclerosis (FSGS) and has received Orphan Drug Designation from both the U.S. FDA and European Medicines Agency (EMA).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68346#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68346"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68346#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest Medicines Licenses DMX-200 from Dimerix \u2013 CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68346","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68346"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68346\/revisions"}],"predecessor-version":[{"id":68348,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68346\/revisions\/68348"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68346"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68346"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68346"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}